Bajaj Healthcare Reports Q2 Profit of Rs 14.09 Crore

Bajaj Healthcare posted a profit after tax of Rs 14.09 crore for the quarter ended September 30, 2026, with revenue from operations reaching Rs 176.90 crore.

Reader Takeaway: Growth is supported by the Genrx Pharmaceuticals acquisition, though divestment timelines remain a key monitorable factor.

What just happened

Bajaj Healthcare has received an order from the NCLT Mumbai Bench approving the acquisition of Genrx Pharmaceuticals on a going concern basis. This entity will become a wholly owned subsidiary of the company. Simultaneously, the company provided a financial update for the second quarter, showing stable earnings with a Basic EPS of Rs 4.19 for the period.

Why this matters

The acquisition of Genrx Pharmaceuticals represents a strategic inorganic expansion for Bajaj Healthcare. Additionally, the company has nearly finished deploying the Rs 204.97 crore raised through a previous preferential issue, with only Rs 5.91 crore remaining unutilized as of September 30, 2026.

Assets and Divestment

Management is actively streamlining operations. The company is in the process of concluding the sale of its unit at MIDC, Tarapur, expected by October 31, 2026. Furthermore, the sale of plots in the Dahej Industrial Area, Gujarat, was successfully completed shortly after the close of the second quarter.

What to track next

Investors should watch for the formal integration of Genrx Pharmaceuticals and the final execution of the Tarapur asset sale. These moves, combined with the efficient utilization of past fund-raises, reflect the company's current focus on balancing core operations with targeted expansion.